23-valent pneumococcal polysaccharide vaccine
Sponsors
Genentech, Inc., Wyeth is now a wholly owned subsidiary of Pfizer, Pfizer, Jiangsu Province Centers for Disease Control and Prevention, Biogen
Conditions
COVID-19InfluenzaInfluenza VaccinesLung Resection SurgeryPneumococcal Conjugate VaccinePneumococcal DiseasePneumococcal InfectionPneumococcal Infectious Disease
Early Phase 1
Phase 1
Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above
CompletedNCT05815264
Start: 2020-09-07End: 2021-04-06Updated: 2026-01-02
Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine
CompletedNCT06703203
Start: 2025-07-17End: 2026-02-05Updated: 2026-03-30
Phase 2
A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate
CompletedNCT00282308
Start: 2006-01-23End: 2012-05-28Updated: 2017-08-10
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
CompletedNCT02097849
Start: 2015-02-28End: 2016-05-02Updated: 2017-06-02
Phase 3
Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS
CompletedNCT00574548
Start: 2007-11-30End: 2010-02-28Updated: 2011-07-22
A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older
CompletedNCT01646398
Start: 2012-06-30End: 2012-10-31Updated: 2013-09-20
Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above
CompletedNCT04278248
Start: 2018-01-12End: 2018-06-07Updated: 2020-02-20
A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
RecruitingNCT06044077
Start: 2023-09-08End: 2029-07-31Target: 1920Updated: 2023-09-21
Phase 4
A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)
CompletedNCT01163747
Start: 2010-09-30End: 2012-06-30Updated: 2012-12-07
Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults
CompletedNCT02062281
Start: 2013-11-30End: 2014-01-31Updated: 2014-02-13
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease
CompletedNCT03762824
Start: 2016-06-14End: 2020-12-21Updated: 2023-03-29
A Clinical Trial to Evaluate the Immunogenicity and Safety of PPV23 Vaccine Revaccinations in the Elderly
CompletedNCT04701788
Start: 2021-03-30End: 2022-02-15Updated: 2022-02-16
A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old
CompletedNCT04700618
Start: 2021-03-21End: 2022-02-13Updated: 2022-02-16
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine
CompletedNCT04953325
Start: 2021-07-09End: 2022-01-31Updated: 2022-04-14
Preoperative Pneumococcal and Influenza Vaccination to Prevent Postoperative Pulmonary Infection in Patients Undergoing Lung Resection for Pulmonary Nodules or Lung Cancer
Not yet recruitingNCT07885540
Start: 2026-11-01End: 2028-09-30Target: 1278Updated: 2026-10-21
Unknown Phase
Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.
NCT04551248
Start: 2021-08-01End: 2022-03-31Target: 1000000Updated: 2020-09-16
A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population
CompletedNCT07071701
Start: 2022-07-02End: 2024-04-05Updated: 2025-07-17